Literature DB >> 33425745

Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis.

Rixin Zhang1, Tiegang Li1, Weiqi Wang1, Wenqiang Gan1, Silin Lv1, Zifan Zeng1, Yufang Hou1, Zheng Yan1, Min Yang1.   

Abstract

BACKGROUND: The Immunoscore method, based on the distribution of the quantification of cytotoxic and memory T cells, provides an indicator of tumor recurrence for colon cancer. However, recent evidence has suggested that immune checkpoint expression represents a surrogate measure of tumor-infiltrating T cell exhaustion, and therefore may serve as a more accurate prognostic biomarker for colon cancer. Indoleamine 2, 3-dioxygenase 1 (IDO1), a potent immunosuppressive molecule, has been strongly associated with T-cell infiltration, but it lacks universal prognostic significance among all of the cancer subtypes. Our aim was to elucidate the prognostic significance of the combination of IDO1 and CD8A expression in colon cancer.
METHODS: Gene expression and clinical survival data were analyzed using The Cancer Genome Atlas (TCGA) data set and validated using NCBI Gene Expression Omnibus (NCBI-GEO) cohort. Hierarchical clustering, functional enrichment analyses, and immune infiltration analysis were applied to evaluate the distinctive immune statuses in colon cancer risk subgroups stratified by IDO1 and CD8A expression. Moreover, Multivariate Cox regression analysis and Receiver Operating Characteristic (ROC) analyses were conducted to determine the prognostic value of IDO1/CD8A stratification. The IDO1/CD8A classifier may be suitable for use in the prediction of cancer development. It was validated via an in vivo murine model.
RESULTS: The stratification analysis demonstrated that the colon cancer subtype with the CD8AhighIDO1high* tumor resulted in the worst survival despite high levels of CD8 infiltrates. Its poor prognosis was associated with high levels of immune response, checkpoint genes, and Th1/IFN-γ gene signatures, regardless of CMS classification. Moreover, the IDO1/CD8A stratification was identified as an independent prognostic factor of overall survival (OS) and a useful predictive biomarker in colon cancer. In vivo data revealed the CD8AhighIDO1high group showed strong correlations with late-stage metastasis of colon carcinoma cells and upregulation of immune checkpoints.
CONCLUSIONS: The findings indicate that the proposed IDO1/CD8A stratification has exact and independent prognostic implications beyond CD8 T cell alone and CMS classification. As a result, it may represent a promising tool for risk stratification in colon cancer and improve the development of immunotherapies for patients with colon cancer in the future.
Copyright © 2020 Zhang, Li, Wang, Gan, Lv, Zeng, Hou, Yan and Yang.

Entities:  

Keywords:  colon cancer; immune checkpoint; immune subtype; prognosis; tumor microenvironment

Year:  2020        PMID: 33425745      PMCID: PMC7793995          DOI: 10.3389/fonc.2020.594098

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  60 in total

1.  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.

Authors:  Christoph Reissfelder; Slava Stamova; Christina Gossmann; Marion Braun; Andreas Bonertz; Ute Walliczek; Mario Grimm; Nuh N Rahbari; Moritz Koch; Maral Saadati; Axel Benner; Markus W Büchler; Dirk Jäger; Niels Halama; Khashayarsha Khazaie; Jürgen Weitz; Philipp Beckhove
Journal:  J Clin Invest       Date:  2014-12-22       Impact factor: 14.808

Review 2.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review.

Authors:  Bagher Farhood; Masoud Najafi; Keywan Mortezaee
Journal:  J Cell Physiol       Date:  2018-11-22       Impact factor: 6.384

3.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

Authors:  Qing Zhou; Meghan E Munger; Rachelle G Veenstra; Brenda J Weigel; Mitsuomi Hirashima; David H Munn; William J Murphy; Miyuki Azuma; Ana C Anderson; Vijay K Kuchroo; Bruce R Blazar
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

Review 4.  Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Authors:  Rodrigo Dienstmann; Louis Vermeulen; Justin Guinney; Scott Kopetz; Sabine Tejpar; Josep Tabernero
Journal:  Nat Rev Cancer       Date:  2017-01-04       Impact factor: 60.716

Review 5.  Influence of human immune cells on cancer: studies at the University of Colorado.

Authors:  Tullia C Bruno; Jena D French; Kimberly R Jordan; Oscar Ramirez; Trisha R Sippel; Virginia F Borges; Bryan R Haugen; Martin D McCarter; Allen Waziri; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

6.  Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.

Authors:  Marwan Fakih; Ching Ouyang; Chongkai Wang; Travis Yiwey Tu; Maricel C Gozo; May Cho; Marvin Sy; Jeffrey A Longmate; Peter P Lee
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

7.  Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Authors:  Lijie Zhai; Erik Ladomersky; Kristen L Lauing; Meijing Wu; Matthew Genet; Galina Gritsina; Balázs Győrffy; Priscilla K Brastianos; David C Binder; Jeffrey A Sosman; Francis J Giles; Charles D James; Craig Horbinski; Roger Stupp; Derek A Wainwright
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

8.  Dynamic host immune response in virus-associated cancers.

Authors:  Song Cao; Kristine M Wylie; Matt A Wyczalkowski; Alla Karpova; Jessica Ley; Sam Sun; R Jay Mashl; Wen-Wei Liang; Xiaowei Wang; Kimberly Johnson; John F DiPersio; Hiram Gay; Lee Ratner; Feng Chen; Douglas R Adkins; Li Ding
Journal:  Commun Biol       Date:  2019-03-22

9.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Authors:  Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry
Journal:  Nat Immunol       Date:  2008-11-30       Impact factor: 25.606

Review 10.  Colorectal cancer prevention: Immune modulation taking the stage.

Authors:  Rochelle Fletcher; Yi-Jun Wang; Robert E Schoen; Olivera J Finn; Jian Yu; Lin Zhang
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 11.414

View more
  3 in total

1.  A novel high-risk subpopulation identified by CTSL and ZBTB7B in gastric cancer.

Authors:  Kaisa Cui; Surui Yao; Bingxin Liu; Shengbai Sun; Liang Gong; Qilin Li; Bojian Fei; Zhaohui Huang
Journal:  Br J Cancer       Date:  2022-08-08       Impact factor: 9.075

2.  Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.

Authors:  Yufang Hou; Rixin Zhang; Jinbao Zong; Weiqi Wang; Mingxuan Zhou; Zheng Yan; Tiegang Li; Wenqiang Gan; Silin Lv; Zifan Zeng; Min Yang
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

3.  Prognostic Values and Underlying Regulatory Network of Cohesin Subunits in Esophageal Carcinoma.

Authors:  Wenqiang Gan; Weiqi Wang; Tiegang Li; Rixin Zhang; Yufang Hou; Silin Lv; Zifan Zeng; Zheng Yan; Min Yang
Journal:  J Cancer       Date:  2022-03-06       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.